RxDoctor Payments Data

Larry Kestin

Radiation Oncology · Pontiac, MINPI 1073572434

Payments from drug & device makers

What this record shows

20 manufacturers reported payments, led by Visionrt, Inc. at 36.8% of the total. Reporting peaked in 2024 at $2,472 and has fallen 74.6% since, to $629 in 2025.

$5,829in general payments, 2019–2025

Across 57 payments — averaging $102.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Visionrt, Inc.$2K
  • Elekta, Inc.$1K
  • Viewray Technologies Inc$535
  • Siemens Medical Solutions USA, Inc.$387
  • Accuray Incorporated$191
  • Zap Surgical Systems, Inc.$173
  • plus $986 from 14 others
$152,548in research payments, 2019–2025

Across 2 payments — averaging $76,274 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$153K

What the payments were for

  • Travel & lodging$2,58644%
  • Food & beverage$3,24356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,829 in reported general payments places this provider in the 85th percentile of 198 radiation oncology providers in Michigan.

See all radiation oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$863,368
Medicare patients
151
Services billed
3,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$11,271
Memantine Hcl23$1,136
Tamsulosin Hcl17$280
Sucralfate11$247

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →